{
  "ticker": "LTP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973642",
  "id": "02973642",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7my5c407f9w.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n#### **Operational Highlights:**  \n- **SPONTAN\u00ae pharmacy distribution** commenced via Symbion\u2019s 3,900-location network; initial prescriptions under TGA Special Access Scheme generated **$30k** receipts.  \n- **ROXUS\u00ae** on track for **US launch H1 CY2026**; GMP manufacturing process underway.  \n- **OROFLOW\u00ae** collaboration signed for **$4.5B global market** (oesophageal disorders); proof-of-concept testing initiated.  \n- **FDA-aligned Phase II pharmacokinetic study** preparations completed; patient enrolment expected **Q1 CY2026**.  \n\n#### **Financial Highlights:**  \n- **Cash balance: $31.8M** (30 June 2025); **37 quarters of funding runway** at current burn rate.  \n- **Net operating cash outflow: $0.9M** (quarter); **R&D tax incentive: $1.0M** received.  \n- **Total R&D spend: $1.0M** (quarter).  \n\n#### **Upcoming Catalysts:**  \n- **ROXUS US launch** (H1 CY2026).  \n- **SPONTAN Phase II trial** enrolment (Q1 CY2026).  \n- **EMA engagement** for EU market pathway (H2 CY2025).  \n\n*No material capital-raising, M&A, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 5198,
    "completion_tokens": 306,
    "total_tokens": 5504,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T22:57:46.335540"
}